ライフサイエンスコーパス: reduce the risk of

1 e, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascula

2 BCG vaccination reduced the risk of a positive baseline IGRA (relative r

3 Tocilizumab significantly reduced the risk of a subsequent NMOSD relapse compared

4 is suggest that higher physical activity may reduce the risk of abdominal aortic aneurysm, however, f

5 traction, it is possible to reduce the FIO2, reduce the risk of absorption atelectasis, and maintain

6 ily single-inhaler FF/UMEC/VI triple therapy reduced the risk of ACM versus UMEC/VI in patients with

7 gs indicate that eating a healthy diet might reduce the risk of acquired hearing loss.

8 nofovir disoproxil fumarate-based therapy to reduce the risk of acquisition of HIV infection in perso

9 e carbon debt with prescribed fire will help reduce the risk of additional mortality from wildfire, b

10 induced abortion before conceiving again, to reduce the risk of adverse birth outcomes in the subsequ

11 A REMS program to reduce the risk of adverse outcomes, including misuse, a

12 VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb even

13 stigated whether SGLT2 inhibitors could also reduce the risk of AF/AFL.

14 Dapagliflozin reduced the risk of AF/AFL events by 19% (264 versus 325

15 recommendations for the treatment of milk to reduce the risk of AFM(1) contamination.

16 in individuals at higher CVD risk, aiming to reduce the risk of age-related cognitive decline in non-

17 f HIV infection is of substantial benefit in reducing the risk of AIDS-related events or death.

18 Compared with placebo, inebilizumab reduced the risk of an NMOSD attack.

19 tating the allergen at the injection site to reduce the risk of anaphylaxis.

20 Improvements in WSH also reduced the risk of anemia in Bangladesh but did not pro

21 0.005) improved hemoglobin concentration and reduced the risk of anemia, iron deficiency, and iron-de

22 IYCF counseling with LNSs reduced the risks of anemia, iron deficiency, and low vi

23 Alirocumab reduced the risk of any stroke (HR, 0.72 [95% CI, 0.57-0

24 ion of AP morphology is a viable strategy to reduce the risk of arrhythmogenic CaT alternans.

25 he risk of serious asthma-related events and reduced the risk of asthma exacerbation.

26 hora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the

27 asset of pharmacological strategies aimed at reducing the risk of atherosclerotic cardiovascular even

28 Antithrombotic therapies can reduce the risk of atherothrombotic events but increase

29 Farm exposures may reduce the risk of atopic dermatitis (AD) in children, b

30 an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.

31 es should examine whether treatment for MetS reduces the risk of BE.

32 found strong evidence that site familiarity reduces the risk of being predated by lynx, whereas the

33 defect with hemoclips after polyp resection reduces the risk of bleeding.

34 Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these pati

35 hould be considered during implementation to reduce the risk of both known and unknown adverse effect

36 e-duty actions that have strong potential to reduce the risk of both undernutrition, obesity, and DR-

37 ast cancer, whose pharmacological inhibition reduces the risk of breast cancer recurrence.

38 ignificantly slow down somatic evolution and reduce the risk of cancer by limiting the accumulation o

39 n active surveillance for prostate cancer to reduce the risk of cancer progression, dietary approache

40 clear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, an

41 gement of failure to restore oxygenation and reduce the risk of cardiopulmonary arrest.

42 s well as approaches under investigation, to reduce the risk of cardiovascular disease and lower infl

43 velop prevention and treatment strategies to reduce the risk of cardiovascular disease.

44 ring drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease.

45 t the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients wit

46 llitus Patients) empagliflozin significantly reduced the risk of cardiovascular and kidney outcomes i

47 SGLT2i reduced the risk of cardiovascular death or hospitalisat

48 ession of carotid intima-media thickness and reduced the risk of cardiovascular disease in adulthood.

49 s acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared wi

50 Empagliflozin reduces the risk of cardiovascular death or hospitalizat

51 ary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial i

52 whether lowering plasma triglyceride levels reduces the risk of cardiovascular events to the same ex

53 n was superior to culprit-lesion-only PCI in reducing the risk of cardiovascular death or myocardial

54 rving arterial function with ageing, thereby reducing the risk of cardiovascular diseases.

55 ercise training are effective strategies for reducing the risk of cardiovascular events, but multiple

56 arch into medical therapies aimed at further reducing the risks of cardiovascular events in patients

57 the remediation of Cd(II) pollution so as to reduce the risk of Cd(II) enrichment in rice grains and

58 have become routine embolization devices to reduce the risk of cerebral aneurysm bleeding.

59 se, but it is unknown if DHA supplementation reduces the risk of childhood allergies.

60 ucing SFA consumption as much as possible to reduce the risk of chronic diseases, especially cardiova

61 ART may reduce the risk of CIN2+ detection at follow-up; this ef

62 Reducing SU levels is unlikely to reduce the risk of CKD development.

63 pooled analysis showed preventive treatment reduced the risk of clinical seizures (odds ratio [OR] =

64 that anticoagulation in patients with AF may reduce the risk of cognitive decline and dementia.

65 bin thresholds for red-cell transfusions may reduce the risk of cognitive delay among extremely-low-b

66 uld reduce hypoxic exposure and consequently reduce the risk of comorbidities in those with SDB, warr

67 t success rate of orotracheal intubation and reduces the risk of complications when compared with dir

68 coverage may carry an additional benefit of reducing the risk of contracting HIV infection, particul

69 Evolocumab reduced the risk of coronary heart disease death, myocar

70 e of maintaining COC should be emphasized to reduce the risk of CVD among hypertension patients.

71 three actions that should be implemented to reduce the risk of danger: 1) preintubation assessment f

72 intake, demonstrably achievable by many, may reduce the risk of death as a result of breast cancer in

73 Dapagliflozin reduced the risk of death and worsening heart failure an

74 pared with an initial conservative strategy, reduced the risk of death or nonfatal myocardial infarct

75 (targeting <120 or <140 mm Hg, respectively) reduced the risks of death and major cardiovascular even

76 The results confirmed the role of RAASi in reducing the risk of death in COVID-19 patients.

77 ermine whether preoperative oral antibiotics reduce the risk of deep SSIs in elective colorectal surg

78 These fruits could contribute to reduce the risk of degenerative chronic diseases due to

79 To reduce the risk of delayed IH diagnosis, emergency explo

80 llow metapopulations to increase in size and reduce the risk of demographic stochasticity or disaster

81 e through street trees close to the home may reduce the risk of depression, especially for individual

82 aster social cohesion at the community level reduced the risk of depression among women (relative ris

83 f life for patients with advanced cancer and reduces the risk of depression for caregivers.

84 patients with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.

85 ut the host genetic factors that increase or reduce the risk of developing RHD.

86 demonstrated that intensive glucose control reduced the risk of developing diabetic peripheral neuro

87 cause changes in the gut microbiota, thereby reducing the risk of developing CRC.

88 intravenous immunoglobulin (IVIG) treatment reduces the risk of development of coronary artery aneur

89 erefore reducing lifetime exposure, may help reduce the risk of diabetes, independently of obesity se

90 SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death

91 ty of chlorinated drinking water while still reducing the risk of diarrhoea.

92 ion antiretroviral therapy has substantially reduced the risks of diffuse large B-cell lymphoma, Burk

93 Prevention of these infections could reduce the risk of direct death and stunting and deaths

94 In multivariate analyses, laparoscopy reduced the risk of directly related readmissions by 32%

95 addition of daratumumab would significantly reduce the risk of disease progression or death in this

96 n combination with a null-expressing KIR3DL1 reduced the risk of disease (KIR3DL1(HIGH)/KIR3DL1(NULL)

97 Preventive therapy for tuberculosis reduces the risk of disease in people who have been infe

98 To reduce the risk of drug-induced haemolysis, all patients

99 ion of lung cancer at an early stage and can reduce the risk of dying from lung cancer.

100 microbiota requires a 2-pronged strategy to reduce the risk of dysplasia in colitis patients.

101 Notably, a history of statin or SSRI usage reduced the risk of EAC or HGD by 49% or 61%, respective

102 nique properties as sedative agent and might reduce the risk of each complication.

103 ing the prenatal period and in early infancy reduce the risk of early-onset AD, a phenotype associate

104 ACNS0333 therapy significantly reduced the risk of EFS events in patients < 36 months o

105 4 to 6 months and peanut from 4 to 11 months reduced the risk of egg allergy, peanut allergy and egg

106 technologies may be successfully applied to reduce the risk of environmental transmission of hepatit

107 unities for future improvements, which could reduce the risk of escape mutations to this therapeutic

108 the deterioration in glomerular function and reduce the risk of ESKD in large-scale randomized clinic

109 screening and/or preventive strategies will reduce the risk of ESKD in women with adverse pregnancy

110 ional studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients w

111 ly stepped up to achieve symptom control and reduce the risk of exacerbations and stepped down after

112 minate the risk of critical EWL, they do not reduce the risk of exceeding T(opt) (+2% higher).

113 o copies of the C allele in rs3782886 (BRAP) reduced the risk of excessive alcohol consumption.

114 Theory suggests individuals can reduce the risk of exploitation by initially spreading o

115 Such approaches may in the future reduce the risk of failure in single-target and symptom-

116 nd remodeling pathways and could potentially reduce the risk of fibrostenotic complications.

117 late status in women of reproductive age and reduce the risk of folic acid-responsive neural tube bir

118 nvironmental monitoring (EM) is essential to reduce the risk of foodborne illness but is complicated

119 Odanacatib reduced the risk of fracture, but was associated with an

120 surgical patients having surgery, CCRTs may reduce the risk of FTR among patients having orthopedic

121 roids (ICS) is controversial, because it can reduce the risk of future exacerbations of the disease a

122 egulating unsafe wildlife trade practices to reduce the risk of future pandemics.

123 r appropriate antibiotic administration that reduces the risk of GAS sequelae and limits spread of th

124 Efficacious decontamination reduces the risk of harm to those directly affected and

125 6-7.47), whereas KIR3DL1(HIGH)/KIR3DL1(NULL) reduced the risk of having purely mucocutaneous disease

126 rated that antiviral therapy with NUCs could reduce the risk of HCC recurrence after curative treatme

127 SVR reduced the risk of HCC.

128 tion, either with IFN or NUCs, substantially reduces the risk of HCC development, even if antiviral t

129 Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and car

130 t do not have effective treatment as well as reduce the risk of heart failure that is associated with

131 ment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with

132 ortant role in blood pressure regulation and reducing the risk of heart failure.

133 l relationships should develop gradually, to reduce the risk of helpers being exploited.

134 While opioid agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition

135 To reduce the risk of hernia recurrence, the optimal timing

136 ht be amenable to pharmacological therapy to reduce the risk of HF in the context of type 2 diabetes

137 Although each individual intervention can reduce the risk of HIV acquisition among PWID, there is

138 uld be leveraged to increase use of PrEP and reduce the risk of HIV acquisition.

139 lls have anti-HIV activity: they are able to reduce the risk of HIV infection and/or slow HIV disease

140 Antiretroviral therapies greatly reduce the risk of HIV-related PML, but many modern trea

141 re-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition.

142 hylaxis (PrEP) is an effective strategy that reduces the risk of HIV acquisition; however, uptake amo

143 t to determine how antibodies contributed to reducing the risk of HIV-1 acquisition in a phase IIb pr

144 Sodium-glucose cotransporter-2 inhibitors reduce the risk of hospitalization for heart failure (HH

145 s, sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure (HH

146 m-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or

147 a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for heart failure (H

148 rate-reduced, high-protein (CRHP) diet might reduce the risk of hypoglycemia and therefore compared t

149 fective antidiabetic agent and substantially reduces the risk of hypoglycemia, few studies have exami

150 Tight glucose monitoring reduces the risk of hypoglycemia, which can result in a

151 lose monitoring and early intervention might reduce the risk of hypomanic or manic symptoms in women

152 terval {CI} .83-.97]; P = .01), and strongly reduced the risk of IGRA conversion (RR, 0.56 [95% CI, .

153 eptor (CAR) T-cell targeting in an effort to reduce the risk of immune escape in pediatric B-cell acu

154 guiding precision immunotherapy treatment to reduce the risk of immune-related cardiotoxicity.

155 n effect predicts increasing biodiversity to reduce the risk of infection, but the generality of this

156 ither probiotics or synbiotics significantly reduced the risk of infectious complications following a

157 om red meat using bacterial sialidases could reduce the risk of inflammatory diseases associated with

158 Vaccine significantly reduced the risk of influenza illness by >40% with no ef

159 packaged in a nonintegrating lentivector to reduce the risk of insertional mutagenesis.

160 receive dual antiplatelet therapy (DAPT) to reduce the risk of ischemic complications.

161 Y(12) inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with a

162 pared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or de

163 vent analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovas

164 On the contrary, prematurity reduced the risk of its use.

165 hlight therapeutic windows of opportunity to reduce the risk of late-onset Alzheimer's disease.

166 Any vigorous exercise reduced the risk of LGA in underweight and normal-weight

167 om an AI system to provide standard care can reduce the risk of liability by accepting, rather than r

168 atheter ablation and mitral valve surgery in reducing the risk of life-threatening arrhythmias, as we

169 prove beneficial in the most severe cases by reducing the risk of losing the globe altogether.

170 by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% c

171 in and a P2Y(12) inhibitor has been shown to reduce the risk of major adverse cardiovascular events (

172 Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (

173 ed to standard therapy did not significantly reduce the risk of major adverse cardiovascular events.

174 d showed that PCSK9 inhibitors significantly reduce the risk of major vascular events.

175 herapy 1 to 3 months after PCI significantly reduced the risk of major bleeding by 40% compared with

176 atran 110 mg (0.81, 0.71-0.94) significantly reduced the risk of major bleeding compared with usual w

177 LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in ol

178 et therapy, or vitamin K antagonists further reduces the risk of major adverse cardiovascular events

179 1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among pa

180 DL-C) concentration of <70 mg/dL in terms of reducing the risk of major cardiovascular events in 2860

181 cation of glucose-lowering therapy is key to reducing the risk of major vascular outcomes.

182 ly that suppression of de novo infection may reduce the risk of malignant transformation.

183 ), we find that primary infection appears to reduce the risk of medically attended infection with tha

184 To reduce the risk of medication-related errors, antiretrov

185 y in the joints, entheses and skin, but also reduce the risk of metabolic comorbidities and improve t

186 CHO intake induces CPT1A methylation, hence reducing the risk of metabolic diseases, whereas FAT int

187 There are currently no proven treatments to reduce the risk of mild cognitive impairment and dementi

188 Intensive BP control significantly reduced the risk of mild cognitive impairment (14.6 vs 1

189 ensities did best to move slowly and thereby reduce the risk of missing their stray partner, who is t

190 n, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hos

191 ded to other guideline-recommended therapies reduced the risk of mortality and heart failure hospital

192 ons may constrain Cx. abundance, which could reduce the risk of mosquito-borne disease while helping

193 g for HIV can inform use of interventions to reduce the risk of mother-to-child transmission.

194 that combination ART is highly effective at reducing the risk of mother-to-child transmission, with

195 proteins (e.g. Cas9 protein) is desirable to reduce the risk of mutagenesis from off-target activity.

196 ADH1B*2 reduces the risk of NASH and fibrosis in adults with NAF

197 nt, while also improving slope stability and reducing the risk of natural hazards.

198 ings may facilitate reendothelialization and reduce the risk of neoatherosclerosis.

199 e case finding or home-based surveillance to reduce the risk of non-differential misclassification of

200 compared to formula fed infants and this can reduce the risk of obesity and metabolic syndrome later

201 This system reduces the risk of off-target mutations and minimizes t

202 ve was to ascertain whether PCSK9 inhibition reduces the risk of PAD events or VTE after acute corona

203 srupt undesirable host-insect interaction to reduce the risk of pathogen transmission to humans.

204 corporated into PPE guidance and training to reduce the risk of pathogen transmission.

205 ith allograft rejection or CMV infection may reduce the risk of PCP.

206 hat timely introduction of peanut to infants reduces the risk of peanut allergy.

207 Antibiotic prophylaxis may reduce the risk of pelvic infection, which is an importa

208 ative, and postoperative strategies aimed at reducing the risk of perioperative stroke and at improvi

209 ompared with placebo, corticosteroid therapy reduced the risk of persistent or progressive stromal ke

210 emotion regulation abilities hold promise in reducing the risk of poor mental health as adolescents n

211 rdial ischaemia and infarct size and thereby reduce the risk of post-STEMI complications and heart fa

212 Using smaller endotracheal tubes may reduce the risk of postextubation aspiration.

213 city of a protein before the synthesis would reduce the risk of potential hazards.

214 int, where species adjust their behaviour to reduce the risk of predation, has not been considered.

215 nt patterns when developing interventions to reduce the risk of premature mortality.

216 r improves maternal oral health but fails to reduce the risk of preterm birth.

217 SGLT2i reduced the risk of progression of renal disease by 45%

218 ioxidant vitamins and zinc (plus copper) for reducing the risk of progression to late AMD, these 2 st

219 s B (CHB) is effective and can substantially reduce the risk of progressive liver disease and hepatoc

220 vegetable consumption did not significantly reduce the risk of prostate cancer progression.

221 ggest that the use of 3-piece IOL models may reduce the risk of pseudophakic VAO in children younger

222 We examined whether FA supplementation could reduce the risk of PTD associated with maternal exposure

223 customised to changing anatomy, potentially reducing the risk of radiation-related toxicities while

224 Preventing such declines can reduce the risk of re-injury and improve recovery of nor

225 rrent treatment of TB and HIV to potentially reduce the risk of reactivation of TB due to HIV to info

226 e adjuvant treatments are urgently needed to reduce the risk of recurrence of kidney cancer and of dy

227 ocrine therapy to 10 years has been shown to reduce the risk of recurrence only in a subset of women

228 esection for uncomplicated diverticulitis to reduce the risk of recurrence or colostomy, no prior stu

229 To reduce the risk of recurrence, patients should consume a

230 d to improve the detection of tumors and can reduce the risk of recurrence.

231 intervention was successful in significantly reducing the risk of recurrence of dental caries in chil

232 randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of l

233 lthough cholesterol-lowering medications can reduce the risk of recurrent cardiovascular events, prem

234 est that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral h

235 whether starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral h

236 at a 10 mg/kg dosage as adjunctive treatment reduced the risk of recurrent CDI over placebo for adult

237 Addition of ezetimibe to statin therapy reduces the risk of recurrent cardiovascular (CV) events

238 Ts based on ICD-electrograms is feasible and reduces the risk of recurrent VT.

239 In iPS cell (iPSC)-based transplantation, to reduce the risk of rejection, it is thought to be optima

240 l immunoglobulin-like receptors (KIRs) could reduce the risk of relapse after allogeneic hematopoieti

241 tibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelit

242 zapine compared with sertraline plus placebo reduced the risk of relapse over 36 weeks.

243 Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients w

244 Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3

245 Atrasentan reduced the risk of renal events in patients with diabet

246 rved ejection fraction, sacubitril/valsartan reduced the risk of renal events, and slowed decline in

247 train stability under mass rearing and could reduce the risk of resistance in the field if fertile ma

248 ulizer was found to be safe and effective in reducing the risk of respiratory failure in the 72 hours

249 Background Drug-eluting stents reduce the risk of restenosis in patients undergoing per

250 nts, especially during the rainy season, may reduce the risk of salmonellosis.

251 e muscle mass during aging and may therefore reduce the risk of sarcopenia.

252 m alone or in combination with vitamin D may reduce the risk of SCC, but not BCC.

253 can be incorporated in surgical practice to reduce the risk of SCS infection.

254 Better methods are needed to reduce the risk of self-contamination while doffing pers

255 Sodium-glucose cotransporter 2 inhibitors reduce the risk of serious heart failure and adverse ren

256 e susceptibility to SARS-CoV-2 infection but reduce the risk of severe COVID-19.

257 tality settings, seroconversion dramatically reduced the risk of severe rotavirus gastroenteritis (HR

258 vel evidence indicates that incisional iNPWT reduces the risk of SSI with limited heterogeneity.

259 Compared to usual care, PSM significantly reduced the risk of stroke (risk ratio [RR] 0.24, 95% CI

260 The use of OAC reduces the risk of stroke and death.

261 erly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events duri

262 dations for software developers and users to reduce the risk of such errors.

263 Whether PCI of nonculprit lesions further reduces the risk of such events is unclear.

264 ts as these symptoms may provide targets for reducing the risks of suicidal behaviors.

265 andard wound dressing, did not significantly reduce the risk of surgical-site infection.

266 provide high-certainty evidence that heparin reduces the risk of symptomatic venous thromboembolism f

267 IPT reduced the risk of TB by approximately 30% (aHR, 0.71 [

268 , used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant

269 erquartile range, 2.0-3.4 years), finerenone reduced the risk of the composite cardiovascular outcome

270 opriate contacts to FTC alerts independently reduced the risk of the primary end point (hazard ratio,

271 Compared with placebo, dapagliflozin reduced the risk of the primary end point across each of

272 Empagliflozin reduced the risk of the primary outcome in patients with

273 Sacubitril/valsartan reduced the risk of the primary outcome irrespective of

274 Lorcaserin reduced the risk of the primary renal composite outcome

275 bility at key position 226 is not tolerated, reducing the risk of them being acquired naturally.

276 phylaxis is one approach that can be used to reduce the risk of these infections.

277 Therefore, reducing the risk of these antibodies remains a clinical

278 components of metabolic syndrome are key in reducing the risk of these events.

279 Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a m

280 rogression of atherosclerotic disease and in reducing the risk of thrombosis in the setting of plaque

281 ecessary period of proteasome inhibition and reduce the risk of toxicity from long-term treatment.

282 lied to rapidly improve clinical outcome and reduce the risk of toxicity.

283 ses and formulation of isolation policies to reduce the risk of transmission.

284 their enzymatic activities might be used to reduce the risk of tumor recurrence in patients undergoi

285 eatment of stage III melanoma, substantially reducing the risk of tumor recurrences.

286 tion by repurposing existing therapeutics to reduce the risk of type 2 diabetes.

287 ercise has a central role in human health by reducing the risk of type 2 diabetes, obesity, stroke an

288 G antibodies and IgG containing ICs may also reduce the risk of venous thromboembolism.

289 aluate whether extended-duration rivaroxaban reduces the risk of venous and arterial fatal and major

290 ng and eliminates the need for removal, thus reducing the risk of vessel trauma.

291 B51 positivity, found in 36 (9%) recipients, reduced the risk of viremia approximately fivefold (haza

292 lutinin during human infection is rare, thus reducing the risk of virus adaptation to humans.IMPORTAN

293 th Elevated Risk) testing whether evolocumab reduces the risk of VTE events (deep venous thrombosis o

294 PCSK9 inhibition significantly reduces the risk of VTE.

295 hlorine disinfection in low-income countries reduces the risk of waterborne illness but initiates exp

296 uppression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately a

297 cose cotransporter 2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in

298 low-level evidence indicates that iNPWT also reduces the risk of wound dehiscence, skin necrosis, and

299 e number of records open when placing orders reduces the risk of wrong-patient order errors.

300 e dissemination at human-swine interfaces to reduce the risk of zoonotic infections and to inform pan